Stem Cell Therapy for Pets: Is It Coming Soon?

SAN DIEGO, July 4, 2025

Stem Cell Therapy for Pets?

Gallant secures funding for innovative treatments.

• Gallant received $18 million in funding.
• The funding will support the growth of ready-to-use stem cell therapies for pets.
• feline Chronic Gingivostomatitis (FCGS) in cats is a primary target.
• FDA approval for FCGS treatment is anticipated by early 2026.
• Previous studies showed stem cell therapy improved arthritis in dogs.

Revolutionizing Pet Healthcare

Imagine a world where stem cell therapy is readily available for your furry friends; what if a startup was paving the way for such treatments? Gallant, a San Diego startup, is aiming to do just that with its innovative approach to veterinary medicine.

Earlier this week, the company announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to market. If Gallant can pass regulatory muster, the treatment could transform how we care for our pets.

Tackling Feline Mouth Pain

Gallant, now seven years old, is initially targeting Feline Chronic Gingivostomatitis (FCGS), a painful mouth condition in cats. The company anticipates potential FDA approval for their FCGS treatment by early 2026.

What is FCGS? Feline Chronic Gingivostomatitis is a severe inflammatory disease affecting a cat’s mouth, causing significant pain and difficulty eating. Current treatments frequently enough involve managing symptoms rather than a cure.

Stem cells: Promising But Experimental

Stem cell research has been ongoing for decades in human medicine, and the field is showing encouraging results in animals, too. Such as, studies on dogs with arthritis showed improvements in pain and mobility, with some benefits lasting up to two years.

However, similar treatments for kidney disease in cats have yielded more mixed results. Having mentioned that, kidney disease is another condition Gallant wants to address.

Convenience is Key

What sets Gallant’s approach apart is its focus on convenience. Current stem cell treatments often require harvesting cells from the patient or matched donors. Gallant’s therapy uses ready-to-use cells from donor animals, even across species.

Cross-Species Stem Cells: Using stem cells from donor animals across species could considerably reduce the time and cost associated with current stem cell therapies. This approach could make the treatment more accessible to pet owners.

Investor Confidence

Investors are clearly enthusiastic about the potential of this approach. The funding round was led by Digitalis Ventures, with participation from NovaQuest Capital Management, which previously invested in the first FDA-approved human stem cell therapy.

Did you know? Gallant has raised at least $44 million from investors to date.

Company Leadership

Gallant’s founder, Aaron Hirschhorn, previously sold DogVacay to Rover, its biggest competitor in the dog-sitting marketplace. Hirschhorn passed away in 2021. Linda Black, who joined Gallant nearly at its inception as president and chief scientific officer, now leads the company.

The Science Behind Stem Cell Therapy

So how does this exciting new technology work? Stem cell therapy for pets leverages the body’s natural ability to heal itself. Stem cells have the unique ability to develop into different cell types, offering the potential to repair damaged tissues [[3]].

The process typically begins with the introduction of stem cells into the animal’s body.These cells can be harvested from the animal itself (autologous) or from a donor (allogeneic),such as in Gallant’s case [[2]]. Once there, the stem cells can:

• Reduce inflammation.
• Promote tissue repair.
• Help regenerate damaged cells.

in the context of FCGS,stem cells may help to reduce the inflammation and pain associated with the condition,potentially restoring the health of the cat’s oral tissues. Research into the use of stem cell therapy is on-going, but the results thus far are promising.

Beyond FCGS: Potential Applications of Stem Cell Therapy

While Gallant is starting with FCGS,the potential applications of stem cell therapy in veterinary medicine extend far beyond feline mouth conditions. Stem cells coudl potentially treat other ailments, including:

• Arthritis and joint disorders [[2]].
• Ligament and muscle injuries.
• kidney disease.

Stem cell therapy can potentially treat several issues in pets,offering relief from pain,improving mobility,and extending lifespans. However, it’s essential to recognize that while exciting, the field is still evolving, and more research is needed to fully understand the long-term effects and efficacy.

According to Texas A&M Veterinary Medical Teaching Hospital, stem cell therapy is used for bone and joint disorders and uses either autologous or allogeneic cells [[2]].

What to Expect: The Treatment Process

If you’re considering stem cell therapy for your pet, here’s a general overview of the process:

1. Consultation: A veterinarian will assess your pet’s condition, review medical history, and determine if stem cell therapy is appropriate.
2. Cell Sourcing: As Gallant’s treatment involves readily-available donor cells.
3. Governance: Cells are injected directly into the affected area or intravenously.
4. Monitoring: Your pet will be monitored for any adverse reactions. The vet will schedule follow-up appointments.

The convenience of Gallant’s ready-to-use stem cell approach could streamline this process, making it more accessible for pet owners and potentially reducing the logistical complexities of other stem cell treatments.

myths vs.Facts